TY - JOUR
T1 - A Single-Center Retrospective Study of Re-Transplantation After Allograft Failure in Kidney Transplant Recipients
AU - Noguchi, Hiroshi
AU - Miyamoto, Kyoko
AU - Matsukuma, Yuta
AU - Ueki, Kenji
AU - Tsuchimoto, Akihiro
AU - Nakano, Toshiaki
AU - Kaba, Akari
AU - Sato, Yu
AU - Kubo, Shinsuke
AU - Kaku, Keizo
AU - Okabe, Yasuhiro
AU - Nakamura, Masafumi
N1 - Publisher Copyright:
© 2024 Elsevier Inc.
PY - 2024/4
Y1 - 2024/4
N2 - Background: This study aimed to examine the outcomes of kidney retransplantation in patients with allograft failure at Kyushu University. Methods: We reviewed data from 1043 consecutive patients (including 1001 in a first kidney transplantation [KT] group and 42 in a second KT group) who had undergone KT alone at our institution between January 2008 and September 2022. We also studied immunologic risks and outcomes of patients who had undergone preoperative testing for KT at Kyushu University during the same period. Results: No patient received more than 2 transplants. Donor-specific anti-HLA antibody (DSA) had been detected in a greater percentage of patients in the second KT group than in the first (31% vs 11%, respectively; P < .001). There were no significant differences in 5-year death-censored/overall graft survival rates, rates of surgical complications, or incidence of delayed graft function between the groups. During the study period, significantly more candidates for second than first KT were rejected for this procedure because of their high immunologic risk (20% vs 2%, P < 001). Seven of the 42 patients in the second KT group required the removal of the primary graft during the second transplantation. Conclusion: There is a higher percentage of patients whose DSA has been detected among patients undergoing retransplantation after allograft failure than among those receiving first KTs, which often leads to remaining on the waiting list in the former group. However, if the immunologic risk is within acceptable limits, the graft survival for retransplantation is not inferior to that of a first KT.
AB - Background: This study aimed to examine the outcomes of kidney retransplantation in patients with allograft failure at Kyushu University. Methods: We reviewed data from 1043 consecutive patients (including 1001 in a first kidney transplantation [KT] group and 42 in a second KT group) who had undergone KT alone at our institution between January 2008 and September 2022. We also studied immunologic risks and outcomes of patients who had undergone preoperative testing for KT at Kyushu University during the same period. Results: No patient received more than 2 transplants. Donor-specific anti-HLA antibody (DSA) had been detected in a greater percentage of patients in the second KT group than in the first (31% vs 11%, respectively; P < .001). There were no significant differences in 5-year death-censored/overall graft survival rates, rates of surgical complications, or incidence of delayed graft function between the groups. During the study period, significantly more candidates for second than first KT were rejected for this procedure because of their high immunologic risk (20% vs 2%, P < 001). Seven of the 42 patients in the second KT group required the removal of the primary graft during the second transplantation. Conclusion: There is a higher percentage of patients whose DSA has been detected among patients undergoing retransplantation after allograft failure than among those receiving first KTs, which often leads to remaining on the waiting list in the former group. However, if the immunologic risk is within acceptable limits, the graft survival for retransplantation is not inferior to that of a first KT.
UR - http://www.scopus.com/inward/record.url?scp=85184745305&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85184745305&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2024.01.053
DO - 10.1016/j.transproceed.2024.01.053
M3 - Article
C2 - 38326204
AN - SCOPUS:85184745305
SN - 0041-1345
VL - 56
SP - 488
EP - 493
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 3
ER -